Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells

Cancer Research

Volumn 70, Issue 19, 2010, Pages 7690-7698

  Wu, Colleen ^a   Nik Amini, Saied ^a   Nadesan, Puviindran ^a   Stanford, William L ^b   Alman, Benjamin A ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA CATENIN; BETA1 INTEGRIN; BIOLOGICAL MARKER; CD146 ANTIGEN; CD15 ANTIGEN; HERMES ANTIGEN; PROTEIN STRO 1; UNCLASSIFIED DRUG;

ADIPOCYTE; ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CASE REPORT; CELL DIFFERENTIATION; CELL GROWTH; CHILD; COLONY FORMING UNIT F; CONTROLLED STUDY; DESMOID TUMOR; FEMALE; FIBROBLAST; FIBROMATOSIS; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; INTESTINE POLYP; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR ENGRAFTMENT; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; ALLELES; ANIMALS; BETA CATENIN; CHILD; FEMALE; FIBROMA; HUMANS; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; YOUNG ADULT;

EID: 77957347778     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1656     Document Type: Article

References (47)

1. Shields CJ, Winter DC, Kirwan WO, Redmond HP. Desmoid tumours. Eur J Surg Oncol 2001;27:701-6.
2. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg 1999;229:866-72, discussion 72-3.
3. Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and β-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Eur J Surg Oncol 2009;35:3-10.
4. Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008;23:117-26.
5. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385-98.
6. Scott RJ, Froggatt NJ, Trembath RC, Evans DG, Hodgson SV, Maher ER. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3′ APC gene mutation. Hum Mol Genet 1996;5:1921-4.
7. Hegde MR, Roa BB. Detecting mutations in the APC gene in familial adenomatous polyposis (FAP). Curr Protoc Hum Genet 2006;Chapter 10:Unit 10-8.
8. Tejpar S, Nollet F, Li C, et al. Predominance of β-catenin mutations and β-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-20.
9. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased β-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151:329-34.
10. Tejpar S, Li C, Yu C, et al. Tcf-3 expression and β-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour). Br J Cancer 2001;85:98-101.
11. Fodde R, Edelmann W, Yang K, et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A 1994;91:8969-73.
12. Smits R, van der Houven van Oordt W, Luz A, et al. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology 1998;114:275-83.
13. Riggi N, Cironi L, Provero P, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-68.
14. Riggi N, Cironi L, Provero P, et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006;66:7016-23.
15. Rosland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009;69:5331-9.
16. Li H, Fan X, Kovi RC, et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res 2007;67:10889-98.
17. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007;11:375-88.
18. Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007;67:8216-22.
19. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008;268:1-9.
20. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
21. Weinstein JN. Integromic analysis of the NCI-60 cancer cell lines. Breast Dis 2004;19:11-22.
22. Bonyadi M, Waldman SD, Liu D, Aubin JE, Grynpas MD, Stanford WL. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci U S A 2003;100:5840-5.
23. Kong Y, Poon R, Nadesan P, et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res 2004;64:5795-803.
24. Tolg C, Poon R, Fodde R, Turley EA, Alman BA. Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 2003;22:6873-82.
25. Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 1999;18:5931-42.
26. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002;244:305-18.
27. Cheon SS, Wei Q, Gurung A, et al. β-Catenin regulates wound size and mediates the effect of TGF-β in cutaneous healing. FASEB J 2006;20:692-701.
28. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004;103:1662-8.
29. Phinney DG, Kopen G, Isaacson RL, Prockop DJ. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell Biochem 1999;72:570-85.
30. + marrow cell population is multipotential. Cells Tissues Organs 2002;170:73-82.
31. Noth U, Osyczka AM, Tuli R, Hickok NJ, Danielson KG, Tuan RS. Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. J Orthop Res 2002;20:1060-9.
32. Tuli R, Tuli S, Nandi S, et al. Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells 2003;21:681-93.
33. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its β-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998;153:709-14.
34. Cheon SS, Cheah AY, Turley S, et al. β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A 2002;99:6973-8.
35. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, et al. Deficiency in p53 but not retinoblastoma induces the transformation ofmesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 70:4185-94.
36. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371-9.
37. Crossno JT, Jr., Majka SM, Grazia T, Gill RG, Klemm DJ. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 2006;116:3220-8.
38. Holmes C, Khan TS, Owen C, Ciliberti N, Grynpas MD, Stanford WL. Longitudinal analysis ofmesenchymal progenitors and bone quality in the stem cell antigen-1-null osteoporoticmouse. JBoneMiner Res 2007;22:1373-86.
39. Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 2007;25:1339-47.
40. Sarugaser R, Hanoun L, Keating A, Stanford WL, Davies JE. Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS One 2009;4:e6498.
41. Cho HH, Kim YJ, Kim SJ, et al. Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells. Tissue Eng 2006;12:111-21.
42. Chen Y, Whetstone HC, Lin AC, et al. β-Catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 2007;4:e249.
43. Takahashi-Yanaga F, Sasaguri T. Drug development targeting the glycogen synthase kinase-3β (GSK-3β)-mediated signal transduction pathway: inhibitors of the Wnt/β-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci 2009;109:179-83.
44. Wada A. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 2009;14:1558-70.
45. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 2003;100:15853-8.
46. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, Goodell MA. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 2002;245:42-56.
47. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006;439:84-8.